Medicinal products due diligence questionnaire

The following Life Sciences precedent provides comprehensive and up to date legal information covering:

  • Medicinal products due diligence questionnaire
  • 1 Medicinal Products and Product Pipeline
  • 2 Clinical Trials
  • 3 Orphan Products
  • 4 Product Authorisation
  • 5 Manufacturing
  • 6 Promotion, advertising and interactions with healthcare professionals and patient organisations
  • 7 Pharmacovigilance

Medicinal products due diligence questionnaire

IP COMPLETION DAY: 11pm (GMT) on 31 December 2020 marks the end of the Brexit transition/implementation period entered into following the UK’s withdrawal from the EU. At this point in time (referred to in UK law as ‘IP completion day’), key transitional arrangements come to an end and significant changes begin to take effect across the UK’s legal regime. This document contains guidance on subjects impacted by these changes. Before continuing your research, see Practice Note: What does IP completion day mean for Life Sciences?

Introduction

This medicinal products regulatory due diligence questionnaire relates to the proposed purchase by [insert buyer name] (the Buyer) of the [entire share capital of [insert name of target company] Limited incorporated in England and Wales under number [insert company number] (the Company) OR [insert description of the business to be acquired] (the Business) as a going concern, together with certain assets used in the Business] from [insert seller name] (the Seller) (the Proposed Acquisition).

This questionnaire is designed to enable the Buyer, the Buyer’s solicitors and other professional advisors to obtain the legal information relating to the medicinal products regulatory compliance of the [Company OR Business] which the Buyer requires to assist in the valuation of the [Company OR Business] and with the negotiation of the Proposed Acquisition.

Please answer every question fully. Please provide your answers in

Popular documents